Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SPRO: Glad I gots some, earlier --- looks like maybe WINNER of this entire, dismal, Wall Street day!! (Thinking of getting some of this too??? Well, FIRST see what my Broker, below, has to say about it!!)
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting. The company also develops SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; SPR720, an oral antibiotic, which is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts
Our Aim Is to Identify, Develop and Commercialize Novel Treatments for Multi-Drug Resistant Bacterial Infections and Rare Disease
Spero Therapeutics is a global, multi-asset, clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. Our mission is to become a leader in the field of Gram-negative antibiotics and we aim to achieve this objective by advancing multiple, differentiated products towards commercialization in key territories.
Hope Is at the Core of Our Mission
Spero Therapeutics is highly committed to advancing novel treatment approaches for bacterial infections with a world-class team of biotechnology and biopharmaceutical experts. At Spero Therapeutics, we embrace the Italian word “spero,” which means “hope.” Spero’s mission as the leader in the field of antibiotic drug development is to give hope to patients afflicted with drug resistant infections by developing transformative anti-infective medicines.
As we strive to combat the high unmet medical need associated with drug-resistant bacterial infections, our most advanced product candidate, tebipenem HBr, is designed to be the first oral carbapenem-class antibiotic for use in adults to treat multi-drug resistant (MDR) Gram-negative infections. In September 2020, we announced positive Phase 3 data for tebipenem HBr for the treatment of complicated urinary tract infection (cUTI). If approved by the FDA, tebipenem HBr would be the first oral cUTI drug to earn approval in 26 years, which would be an important achievement given the high levels of resistance to currently available oral therapies. Treatment with effective orally administered antibiotics may help avoid hospitalization and in hospital setting it may help accelerate hospital discharge by delivering a more convenient and cost-effective treatment for patients.
We are also developing SPR720, an oral antibacterial agent currently under development for the treatment of non-tuberculous mycobacterial (NTM) disease, a rare orphan disease.
Additionally we have a platform technology known as our Potentiator Platform. Our product candidate from this platform, SPR206, is an IV-administered agent being developed as an innovative option to treat MDR Gram-negative bacterial infections.
Founded in 2013, and named as one Boston’s Best Places to Work in 2020 and 2017 by the Boston Business Journal, Spero Therapeutics is also the recipient of the first-ever 2017 Xconomy Startup of the Year Award. We sincerely believe that our novel product candidates will have meaningful impact on patient health and significant commercial applications for the treatment of MDR infections in both the hospital and community settings.